Red Light Holland (TRIP) AI Stock Analysis

• Market Cap: C$6.34M
• Dividend Yield: N/A
• Average Volume (3M): 212.42K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.26
• Revenue Growth: -28.00%
• EPS Growth: 38.46%
• Country: CA
• Employees: N/A
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 422,531,200
• 10 Day Avg. Volume: 258,444
• 30 Day Avg. Volume: 212,422
• PEG Ratio: -0.09
• Price to Book (P/B): 1.18
• Price to Sales (P/S): 4.99
• P/FCF Ratio: -6.05
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 44 Neutral
• Price Target: C$0.02 ▼(-25.00% Downside)
• Action: Upgraded Date: 03/05/26
• Date: Action: Upgraded 03/05/26

The score is primarily held back by weak financial performance (ongoing losses and negative operating/free cash flow) and bearish technicals (trading below key moving averages with negative MACD). Balance-sheet leverage is conservative and revenue growth is strong, but valuation remains difficult to support with a negative P/E and no dividend data.

Positive Factors

Low leverage / solid balance sheet

Low debt and a sizable equity base provide durable financial flexibility, reducing short-term refinancing risk and giving management runway to invest in cultivation capacity, marketing and distribution. This protects against shocks and supports multi-month execution of growth plans.

Revenue scaling and demand traction

Material revenue scaling signals product-market fit in permitted channels and creates a base for future operating leverage. Sustained top-line growth enables incremental margin improvement if fixed costs are spread and supports longer-term commercialization of branded microdosing products.

Branded niche market position in legalized Netherlands

Owning cultivation, manufacturing and branded consumer products in a legalized jurisdiction is a structural advantage: it creates proprietary supply, brand recognition, and multiple go-to-market channels (D2C, retail, wholesale), supporting durable revenue where regulation allows.

Negative Factors

Persistent unprofitability and negative margins

Deep and ongoing operating losses erode equity over time and limit the company’s ability to self-fund expansion. Without sustained margin improvement, losses will pressure returns and increase dependence on external capital, a structural drag on long-term viability.

Negative operating and free cash flow (cash burn)

Continued negative operating and free cash flow reduces strategic flexibility and increases reliance on financing or equity raises. Even with improvement, persistent cash burn can force dilution or capex cuts, constraining long-term investment in R&D and distribution.

Concentration risk: reliance on Netherlands regulatory market

Heavy dependence on a single legalized jurisdiction creates structural regulatory and geographic concentration risk. Adverse rule changes, enforcement shifts, or slower legalization elsewhere could materially reduce addressable market and limit sustainable growth beyond current channels.

Red Light Holland Business Overview & Revenue Model

Company Description

Red Light Holland Corp. (TRIP) is a Canadian company focused on the production and distribution of psilocybin truffles, marketed primarily for recreational and therapeutic use. Operating in the emerging psychedelics sector, Red Light Holland aims to provide high-quality, safe, and consistent products to consumers, leveraging a strong brand presence and innovative cultivation methods. The company is also engaged in education and advocacy efforts surrounding responsible use and the potential benefits of psychedelics.

How the Company Makes Money

Red Light Holland generates revenue primarily through the sale of its psilocybin truffles, which are sold in retail locations and online platforms. The company capitalizes on the growing interest in psychedelics for both recreational and therapeutic purposes. Key revenue streams include direct sales to consumers, partnerships with licensed retailers, and potential collaborations with research institutions focused on psychedelics. Additionally, Red Light Holland may benefit from strategic alliances that enhance its distribution channels, marketing efforts, and educational initiatives, all contributing to its overall earnings.

Red Light Holland Financial Statement Overview

Summary

Strong revenue scaling and a low-leverage balance sheet are positives, but they are outweighed by deeply negative net income, negative operating margins, and continued negative operating/free cash flow (still cash-burning despite some improvement).

Income Statement

Revenue has scaled up materially over time, with TTM (Trailing-Twelve-Months) revenue up sharply versus the prior annual period, showing demand traction. However, profitability remains weak: TTM (Trailing-Twelve-Months) net income is deeply negative and margins are still materially below zero (operating and net), indicating the business has not yet converted growth into sustainable earnings. Gross margin is positive and decent in TTM (Trailing-Twelve-Months), but operating costs continue to overwhelm gross profit.

Balance Sheet

The balance sheet is a relative strength, with low leverage: TTM (Trailing-Twelve-Months) debt is small versus equity and the debt-to-equity ratio is very low. Equity remains sizable, providing financial flexibility and some downside protection. The key weakness is value creation: return on equity is strongly negative in TTM (Trailing-Twelve-Months), reflecting ongoing losses that can erode the equity base over time if not corrected.

Cash Flow

Cash generation remains pressured, with TTM (Trailing-Twelve-Months) operating cash flow and free cash flow both negative, implying the company is still cash-burning. A positive sign is that free cash flow has improved versus the prior annual period (strong positive growth rate), suggesting the burn rate may be moderating. Still, cash flow has not yet turned self-funding, and negative operating cash flow reduces flexibility without external financing.

Breakdown	TTM	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Mar 2020
Income Statement
Total Revenue	4.17M	4.94M	4.75M	3.95M	2.33M	0.00
Gross Profit	1.27M	1.91M	2.02M	1.71M	617.68K	0.00
EBITDA	-4.36M	-3.35M	-6.58M	-4.32M	-8.55M	0.00
Net Income	-4.77M	-4.04M	-7.63M	-5.40M	-14.37M	-325.17K
Balance Sheet
Total Assets	18.20M	21.22M	24.08M	30.14M	32.94M	3.97M
Cash, Cash Equivalents and Short-Term Investments	9.88M	12.27M	14.17M	18.53M	26.62M	1.96M
Total Debt	501.66K	2.18M	1.72M	1.77M	1.50M	86.77K
Total Liabilities	3.58M	3.87M	3.82M	3.80M	3.78M	5.11M
Stockholders Equity	14.69M	17.35M	20.07M	26.06M	28.48M	-1.14M
Cash Flow
Free Cash Flow	-2.69M	-2.01M	-3.92M	-6.45M	-5.28M	-238.35K
Operating Cash Flow	-2.51M	-1.48M	-3.23M	-4.39M	-4.88M	-238.35K
Investing Cash Flow	-1.16M	-525.40K	-650.43K	-3.17M	-582.74K	-1.80M
Financing Cash Flow	-490.68K	445.17K	-206.95K	-114.16K	451.76K	4.01M

Red Light Holland Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.02
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:TRIP, the sentiment is Negative. The current price of 0.02 is above the 20-day moving average (MA) of 0.02, above the 50-day MA of 0.02, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 45.00 is Neutral, neither overbought nor oversold. The STOCH value of 0.00 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:TRIP.

Red Light Holland Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
MUSH	54 Neutral	C$8.53M	-7.07	-99.55%	―	-26.71%	-988.89%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CWEB	51 Neutral	C$162.61M	-1.15	-109.83%	―	-4.23%	37.33%
CURA	50 Neutral	C$2.41B	-8.05	-27.48%	―	-3.38%	-31.35%
TRIP	44 Neutral	C$6.34M	-3.09	-23.76%	―	-28.00%	38.46%
RVV	44 Neutral	C$8.37M	-4.56	-664.21%	―	―	-80.42%
PLTH	42 Neutral	C$71.58M	-0.45	-83.55%	―	2.19%	-91.41%

Red Light Holland Corporate Events

Red Light Holland Narrows Focus as Q3 Revenue Rises but Profits Tighten

Red Light Holland reported third-quarter 2026 results showing an 8.3% year-over-year revenue increase to $1.27 million, but a 13.7% decline in gross profit and a slightly higher adjusted EBITDA loss of $0.71 million, while cash fell to $9.24 million amid investment in Bitcoin ETFs and high-interest savings vehicles. Management highlighted normalized sales versus the prior quarter, lower G&A expenses, the shutdown of shiitake mushroom production at AEM to focus on near-profitable operations, and progress in psilocybin R&D through its DEA-registered partner Irvine Labs, underscoring a strategic pivot toward an R&D-driven model and active evaluation of M&A from a relatively strong balance-sheet position.

The most recent analyst rating on (TSE:TRIP) stock is a Hold with a C$0.02 price target. To see the full list of analyst forecasts on Red Light Holland stock, see the TSE:TRIP Stock Forecast page.